E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
BoomRay will receive up to USD 900 million, comprising an upfront payment and development, regulatory and sales milestone payments from Novartis.
imphoenix82
Novartis is helping improve access to Fabhalta for patients with primary immunoglobulin A nephropathy (IgAN) through a variety of support programmes.
imphoenix82
The targeted radioligand therapy Pluvicto will initially be available through selected hospitals and nuclear medicine centres across India under Novartis’ partnership-led access model.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
